ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00406172
Recruitment Status : Unknown
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
First Posted : December 4, 2006
Last Update Posted : December 5, 2006
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.

Condition or disease Intervention/treatment Phase
Cystoid Macular Edema Drug: Bevacizumab Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Bevacizumab





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Pseudophakic eyes with macular edema

Exclusion Criteria:

  • Other retinopathies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406172


Contacts
Contact: Victoria Cubas-Lorenzo, MD (55) 10841400 ext 1171 retinamex@yahoo.com

Locations
Mexico
APEC Recruiting
México D.F., Mexico, 03040
Contact: Victoria Cubas-Lorenzo, MD    (55) 10841400 ext 1171    retinamex@yahoo.com   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Victoria Cubas-Lorenzo, MD APEC México

ClinicalTrials.gov Identifier: NCT00406172     History of Changes
Other Study ID Numbers: APEC 0016
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: December 5, 2006
Last Verified: November 2006

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents